FLT3 and acute myeloid leukemia: However, the optimal approach to incorporate FLT3 inhibitors into the management of newly diagnosed and relapsed/refractory FLT3‐mutated AML patients remains a matter of dispute and additional, pivotal studies are needed to provide an answer to this important question.